Related Experiment Videos
Thrombolysis for acute myocardial infarction
1Division of Cardiology, University Hospital Gasthuisberg, Herestraat, Leuven, Belgium.
Insights
Thrombolytic therapy for acute myocardial infarction improves survival and reduces infarct size when given within 6 hours. Recent trials clarify its mechanisms beyond early reperfusion, guiding future treatment strategies.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Thrombolysis is standard for acute transmural myocardial infarction.
- Early thrombolytic therapy (within 6 hours) improves outcomes.
- Discrepancies in outcomes suggest mechanisms beyond myocardial salvage.
Purpose of the Study:
- Investigate additional mechanisms of thrombolysis in myocardial infarction.
- Clarify the role of reperfusion versus other effects.
- Evaluate recent large-scale trial data to refine thrombolytic strategies.
Main Methods:
- Analysis of large placebo-controlled trials.
- Review of recent megatrials (GUSTO, EMERAS, LATE).
- Inclusion of a meta-analysis (FTT's collaborative Study Group).
Main Results:
- Thrombolysis reduces infarct size, preserves left ventricular function, and improves survival.
- Beneficial effects observed even after 6 hours.
- Recent trials resolved uncertainties regarding thrombolytic efficacy and mechanisms.
Conclusions:
- Thrombolytic therapy has multiple beneficial mechanisms, including infarct size limitation and remodeling.
- Patient and strategy selection for thrombolysis is critical.
- Recent trial data significantly impacts future therapeutic development for myocardial infarction.
Abstract:
Thrombolysis has become standard treatment in the great majority of patients with an acute transmural myocardial infarction. Large placebo-controlled trials have shown that thrombolytic therapy, when given within 6 hours after onset of symptoms, reduces infarct size, preserves left ventricular function and improves survival. Because of discrepancies observed between the effects of thrombolysis on left ventricular function and survival and since beneficial effects have also been observed in subgroups of patients treated after 6 hours, additional mechanisms of actions (besides salvage of ischemic myocardium) have been supposed: limitation of infarct expansion and left ventricular remodeling, increased electrical stability and provision of collaterals to other myocardial regions. The equal clinical outcome with different agents, in spite of proven differences in efficacy for early recanalization, in GISSI-2/International and ISIS-3 has further challenged the importance of the original pathophysiological mechanism (early reperfusion and myocardial salvage). The results of recent megatrials (GUSTO, EMERAS and LATE) and of a recent meta-analysis (FTT's collaborative Study Group) have resolved many uncertainties. The implications of these recent trials for the selection of both patients and thrombolytic strategies and for the future development of new treatment can not be overestimated.